JPRN-jRCT2031230016
Completed
Phase 1
A Phase 1 Study to Assess the Pharmacokinetics of Olorofim in Healthy Japanese and Caucasian Participants
agata Tsutae0 sites24 target enrollmentApril 10, 2023
ConditionsHealthy adult participants
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Healthy adult participants
- Sponsor
- agata Tsutae
- Enrollment
- 24
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants between ages of 18 and 55 years (inclusive) at the time of signing informed consent
- •\-Participants must be in good health, as determined by a medical history, physical examination, 12\-lead electrocardiogram (ECG), and clinical laboratory evaluations at screening and the day before administration of study intervention (Day\-1\)
- •\-Japanese or Caucasian
- •\-Male or female participant
Exclusion Criteria
- •\-Participants have had surgery that may affect drug absorption, distribution, metabolism, or excretion
- •\-Participants with, or with a history of, any clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking olorofim; or interfering with the interpretation of data
- •\-Participants with resting systolic blood pressure (BP) outside the range of 90 to 140 mmHg, resting diastolic BP outside the range of 60 to 90 mmHg, or pulse rate outside the range of 50 to 100 bpm at screening or Day 1 predose, and considered ineligible by the investigator
- •\-Participants who have hypersensitivity to any of the study interventions or components thereof, or drug or any other clinically significant allergy as considered ineligible by the investigator (excluding mild or seasonal allergies such as contact dermatitis or hay fever)
- •\-Participants who had any malignancy (including lymphoma, leukemia) within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years
- •\-Participants with any clinically relevant history of convulsion (other than childhood febrile convulsion before the age of 6 years), syncope, hypotension, dizziness, and fainting
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
MYCATJapanese Patients with Pulmonary MABC DiseaseJPRN-jRCT2031220211Ho Namkoong10
Completed
Phase 1
A phase I study to assess the pharmacokinetics of a single dose of a slow-release solid injection of EPT1647 in healthy male volunteers/AHealthy male volunteersN/AOther -ACTRN12605000782639Epitan Limited6
Recruiting
Not Applicable
A phase I study to evaluate the pharmacokinetic interactions and safety between Amlodipine/Valsartan combination tablet and Rosuvastatin in healthy adult volunteersDiseases of the circulatory systemKCT0001660Kyung Dong Pharmaceutical57
Withdrawn
Not Applicable
A Phase 1 Pharmacokinetic-Pharmacodynamic Study of Avelumab (MSB00100718C) in Patients with Previously Treated Advanced Stage Classical Hodgkin*s LymphomaHodgkin's Lymphomalymph node cancer10025319NL-OMON43446Pfizer15
Completed
Phase 1
A Phase 1 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Selgantolimod upon Co-administration with a Representative Proton Pump Inhibitor or H2-Receptor AntagonistHepatitis BOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInfection - Other infectious diseasesACTRN12620001019998Gilead Sciences50